A5069580321- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- T-cell and B-cell Immunology
- RNA Interference and Gene Delivery
- Plasma Applications and Diagnostics
- Nanoplatforms for cancer theranostics
- Renal and related cancers
- vaccines and immunoinformatics approaches
- Cancer Cells and Metastasis
- Occupational and environmental lung diseases
- Herpesvirus Infections and Treatments
- Heme Oxygenase-1 and Carbon Monoxide
- Immune cells in cancer
- Pancreatic and Hepatic Oncology Research
- Cancer Research and Treatments
- Acute Lymphoblastic Leukemia research
- SARS-CoV-2 and COVID-19 Research
- Cytomegalovirus and herpesvirus research
- 3D Printing in Biomedical Research
- Immune Response and Inflammation
- Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Plasma Diagnostics and Applications
University of Antwerp
2016-2025
Antwerp University Hospital
2016-2025
Integrated Oncology (United States)
2022-2024
Infectious Diseases Institute
2013-2022
Anzac Research Institute
2015
The University of Sydney
2015
Institute for Stem Cell Biology and Regenerative Medicine
2013
Active immunization using tumor antigen-loaded dendritic cells holds promise for the adjuvant treatment of cancer to eradicate or control residual disease, but so far, most cell trials have been performed in end-stage patients with high loads. Here, a phase I/II trial, we investigated effect autologous vaccination 10 acute myeloid leukemia (AML). The Wilms’ 1 protein (WT1), nearly universal antigen, was chosen as an immunotherapeutic target because its established role leukemogenesis and...
Abstract Breakthroughs in cancer immunotherapies have demonstrated considerable success, though not without limitations. Non‐thermal plasma (NTP) for therapy has been emerging as a potential adjuvant treatment via induction of immunogenic cell death (ICD). Cancer cells undergoing ICD stimulate patient's immune system to mount an anticancer response. While promising, the underlying mechanisms NTP‐induced must be closely examined. Here, interaction between non‐thermal and cancerous is studied....
Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable development over recent decades. However, this field is currently in a state of flux toward niche-applications, owing to paradigm-shifts immuno-oncology mobilized by T cell-targeting immunotherapies. DC vaccines are typically generated using autologous (patient-derived) DCs exposed tumor-associated or -specific antigens (TAAs TSAs), the presence immunostimulatory molecules induce maturation, followed reinfusion...
Abstract Background It remains challenging to obtain positive outcomes with chimeric antigen receptor (CAR)-engineered cell therapies in solid malignancies, like colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC). A major obstacle is the lack of targetable surface antigens that are not shared by healthy tissues. CD70 emerges as interesting target, due its stringent expression pattern tissue apparent role tumor progression a considerable amount malignancies. Moreover, also...
Varicella zoster virus (VZV) typically causes chickenpox upon primary infection. In rare cases, VZV can give rise to life-threatening disease in otherwise healthy people, but the immunological basis for this remains unexplained. We report 4 cases of acute severe infection affecting central nervous system or lungs unrelated, children who are heterozygous missense mutations POLR3A (one patient), POLR3C both (two patients). and encode subunits RNA polymerase III. Leukocytes from all patients...
We evaluate the anti-cancer capacity of plasma-treated PBS (pPBS), by measuring concentrations NO2- and H2O2 in pPBS, treated with a plasma jet, for different values gas flow rate, gap treatment time, as well effect pPBS on cancer cell cytotoxicity, three glioblastoma lines, at exactly same conditions. Our experiments reveal that is cytotoxic all conditions investigated. A small variation between jet liquid surface (10 mm vs 15 mm) significantly affects chemical composition its capacity,...
Adoptive immunotherapy is gaining momentum to fight malignancies, whereby γδ T cells have received recent attention as an alternative cell source natural killer and αβ cells. The advent of largely due their ability recognize target tumor using both innate characteristic receptor (TCR)-mediated mechanisms, capacity enhance the generation antigen-specific responses, potential be used in autologous or allogeneic setting.In this study, we explored beneficial effect immunostimulatory cytokine...
The tumor microenvironment is characterized by regulatory T cells, type II macrophages, myeloid-derived suppressor and other immunosuppressive cells that promote malignant progression. Here we report the identification of a novel BDCA1(+)CD14(+) population myeloid are expanded in melanoma patients present dendritic cell-based vaccines, where they suppress CD4(+) an antigen-specific manner. Mechanistic investigations showed expressed high levels immune checkpoint molecule PD-L1 to hinder...
Increasing the selectivity of cancer treatments is attractive, as it has potential to reduce side-effects therapy. Cold atmospheric plasma (CAP) a novel treatment that disrupts intracellular oxidative balance. Several reports claim CAP be selective, but retrospective analysis these studies revealed discrepancies in several biological factors and culturing methods. Before can conclusively stated selective treatment, importance must investigated. In this study, we evaluated influence cell...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers with a low response to treatment and five-year survival rate below 5%. The ineffectiveness partly because an immunosuppressive tumor microenvironment, which comprises tumor-supportive pancreatic stellate cells (PSCs). Therefore, new therapeutic strategies are needed tackle both PSC cancer (PCCs). Recently, physical cold atmospheric plasma consisting reactive oxygen nitrogen species has emerged as novel option for...
Auranofin (AF) is an FDA-approved antirheumatic drug with anticancer properties that acts as a thioredoxin reductase 1 (TrxR) inhibitor. The exact mechanisms through which AF targets cancer cells remain elusive. To shed light on the mode of action, this study provides in-depth analysis molecular and immunogenicity AF-mediated cytotoxicity in non-small cell lung (NSCLC) line NCI-H1299 (p53 Null) its two isogenic derivates mutant p53 R175H or R273H accumulation. TrxR highly expressed panel 72...